Chronic Kidney Disease
74. Rahman A, Hershey S, Ahmed S, et al., Heart extracellular matrix gene expression profile in the vitamin D receptor knockout mice, J Steroid Biochem Mol Biol, 2007;103:416–9.
75. Mizobuchi M, Nakamura H, Tokumoto M, et al., Myocardial effects of VDR activators in renal failure, J Steroid Biochem Mol Biol, 2010;121:188–92.
76. Park CW, Oh YS, Shin YS, et al., Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism, Am J Kidney Dis, 1999;33:73–81.
77. Thadhani R, Appelbaum E, Chang Y, et al., Vitamin D receptor activation and left ventricular hypertrophy in advanced kidney disease, Am J Nephrol, 2011;33:139–49.
78. Judd SE, Nanes MS, Ziegler TR, et al., Optimal vitamin D status attenuates the age-associated increase in systolic blood pressure in white Americans: results from the third National Health and Nutrition Examination Survey, Am J Clin Nutr, 2008;87:136–41.
79. Kristal-Boneh E, Froom P, Harari G, et al., Association of calcitriol and blood pressure in normotensive men, Hypertension, 1997;30:1289–94.
80. Lind L, Hanni A, Lithell H, et al., Vitamin D is related to blood pressure and other cardiovascular risk factors in middle-aged men, Am J Hypertens, 1995;8:894–901.
81. Scragg R, Sowers M, Bell C, Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey, Am J Hypertens, 2007;20:713-9.
82. Hintzpeter B, Mensink GB, Thierfelder W, et al., Vitamin D status and health correlates among German adults, Eur J Clin Nutr, 2008;62:1079–89.
83. Martins D, Wolf M, Pan D, et al., Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey, Arch Intern Med, 2007;167:1159–65.
84. Forman JP, Giovannucci E, Holmes MD, et al., Plasma 25- hydroxyvitamin D levels and risk of incident hypertension, Hypertension, 2007;49:1063–9.
85. Li YC, Kong J, Wei M, et al., 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system, J Clin Invest, 2002;110:229–38.
86. Fryer RM, Rakestraw PA, Nakane M, et al., Differential inhibition of renin mRNA expression by paricalcitol and calcitriol in C57/BL6 mice, Nephron Physiol, 2007;106:p76–81.
87. Timms PM, Mannan N, Hitman GA, et al., Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders?, QJM, 2002;95:787–96.
88. Equils O, Naiki Y, Shapiro AM, et al., 1,25-Dihydroxyvitamin D inhibits lipopolysaccharide-induced immune activation in human endothelial cells, Clin Exp Immunol, 2006;143:58–64.
89. Martinesi M, Bruni S, Stio M, et al., 1,25-Dihydroxyvitamin D3 inhibits tumor necrosis factor-alpha-induced adhesion molecule expression in endothelial cells, Cell Biol Int, 2006;30:365–75.
90. Branisteanu DD, Leenaerts P, van Damme B, et al., Partial prevention of active Heymann nephritis by 1 alpha, 25 dihydroxyvitamin D3, Clin Exp Immunol, 1993;94:412–7.
91. Makibayashi K, Tatematsu M, Hirata M, et al., A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis, Am J Pathol, 2001;158:1733–41.
92. Panichi V, Migliori M, Taccola D, et al., Effects of 1,25(OH)2D3
in experimental mesangial proliferative nephritis in rats, Kidney Int, 2001;60:87–95.
93. Schwarz U, Amann K, Orth SR, et al., Effect of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats, Kidney Int, 1998;53:1696–705.
94. Hirata M, Makibayashi K, Katsumata K, et al., 22-Oxacalcitriol prevents progressive glomerulosclerosis without adversely affecting calcium and phosphorus metabolism in subtotally nephrectomized rats, Nephrol Dial Transplant, 2002;17:2132–7.
95. Tan X, Li Y, Liu Y, Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy, J Am Soc Nephrol, 2006;17:3382–93.
96. Repo JM, Rantala IS, Honkanen TT, et al., Paricalcitol aggravates perivascular fibrosis in rats with renal insufficiency and low calcitriol, Kidney Int, 2007;72:977–84.
97. Palmer BF, Proteinuria as a therapeutic target in patients with chronic kidney disease, Am J Nephrol, 2007;27:287–93.
98. D'Amico G, Bazzi C, Pathophysiology of proteinuria, Kidney Int, 2003;63:809–25.
99. de Zeeuw D, Remuzzi G, Parving HH, et al., Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL, Kidney Int, 2004;65:2309–20.
100. Peterson JC, Adler S, Burkart JM, et al., Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study, Ann Intern Med, 1995;123:754–62.
101. Jafar TH, Schmid CH, Landa M, et al., Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data, Ann Intern Med, 2001;135:73–87.
102. Remuzzi G, Ruggenenti P, Perico N, Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition, Ann Intern Med, 2002;136:604–15.
103. Ruggenenti P, Perna A, Remuzzi G, Retarding progression of chronic renal disease: the neglected issue of residual proteinuria, Kidney Int, 2003;63:2254–61.
104. Zhang Z, Sun L, Wang Y, et al., Renoprotective role of the vitamin D receptor in diabetic nephropathy, Kidney Int, 2008;73:163–71.
105. Mizobuchi M, Morrissey J, Finch JL, et al., Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats, J Am Soc Nephrol, 2007;18:1796–806.
106. Zhang Z, Zhang Y, Ning G, et al., Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase, Proc Natl Acad Sci U S A, 2008;105:15896–901.
107. Freundlich M, Quiroz Y, Zhang Z, et al., Suppression of renin- angiotensin gene expression in the kidney by paricalcitol, Kidney Int, 2008;74:1394–402.
108. Tan X, Wen X, Liu Y, Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF- kappaB signaling, J Am Soc Nephrol, 2008;19:1741–52.
109. Agarwal R, Acharya M, Tian J, et al., Antiproteinuric effect of oral paricalcitol in chronic kidney disease, Kidney Int, 2005;68:2823–8.
110. Fishbane S, Chittineni H, Packman M, et al., Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial, Am J Kidney Dis, 2009;54:647–52.
111. Alborzi P, Patel NA, Peterson C, et al., Paricalcitol reduces
albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial, Hypertension, 2008;52:249–55.
112. de Zeeuw D, Agarwal R, Amdahl M, et al., Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial, Lancet, 2010;376:1543–51.
113. Yao Q, Axelsson J, Heimburger O, et al., Systemic inflammation in dialysis patients with end-stage renal disease: causes and consequences, Minerva Urol Nefrol, 2004;56:237–48.
114. Cheung WW, Paik KH, Mak RH, Inflammation and cachexia in chronic kidney disease, Pediatr Nephrol, 2010;25:711–24.
115. Baeke F, Takiishi T, Korf H, et al., Vitamin D: modulator of the immune system, Curr Opin Pharmacol, 2010;10:482–96.
116. Jahnsen J, Falch JA, Mowinckel P, et al., Vitamin D status, parathyroid hormone and bone mineral density in patients with inflammatory bowel disease, Scand J Gastroenterol, 2002;37:192–9.
117. Sochorova K, Budinsky V, Rozkova D, et al., Paricalcitol (19-
nor-1,25-dihydroxyvitamin D2) and calcitriol (1,25- dihydroxyvitamin D3) exert potent immunomodulatory effects on dendritic cells and inhibit induction of antigen-specific T cells, Clin Immunol, 2009;133:69–77.
118. Eleftheriadis T, Antoniadi G, Liakopoulos V, et al., Paricalcitol reduces basal and lipopolysaccharide-induced (LPS) TNF- alpha and IL-8 production by human peripheral blood mononuclear cells, Int Urol Nephrol, 2010;42:181–5.
119. Moe SM, Zekonis M, Harezlak J, et al., A placebo-controlled trial to evaluate immunomodulatory effects of paricalcitol, Am J Kidney Dis, 2001;38:792–802.
120. Tentori F, Hunt WC, Stidley CA, et al., Mortality risk among hemodialysis patients receiving different vitamin D analogs, Kidney Int, 2006;70:1858–65.
121. Dobrez DG, Mathes A, Amdahl M, et al., Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings, Nephrol Dial Transplant, 2004;19:1174–81.
122. Palmer SC, McGregor DO, Macaskill P, et al., Meta-analysis: vitamin D compounds in chronic kidney disease, Ann Intern Med, 2007;147:840–53.
123. Palmer SC, McGregor DO, Craig JC, et al., Vitamin D compounds for people with chronic kidney disease requiring dialysis, Cochrane Database Syst Rev, 2009;CD005633.
124. Mix TC, St peter WL, Ebben J, et al., Hospitalization during advancing chronic kidney disease, Am J Kidney Dis, 2003;42:972–81.
125. Smith DH, Gullion CM, Nichols G, et al., Cost of medical care for chronic kidney disease and comorbidity among enrollees in a large HMO population, J Am Soc Nephrol, 2004;15:1300–6.
126. Nuijten M, Andress DL, Marx SE, et al., Chronic kidney disease Markov model comparing paricalcitol to calcitriol for secondary hyperparathyroidism: a US perspective, Curr Med Res Opin, 2009;25:1221–34.
127. Gal-Moscovici A, Sprague SM, Comparative cost-benefit analyses of paricalcitol and calcitriol in stage 4 chronic kidney disease from the perspective of a health plan, Clin Drug Investig, 2007;27:105–13.
128. Nuijten M, Andress DL, Marx SE, et al., Cost Effectiveness of Paricalcitol versus a non-selective vitamin D receptor activator for secondary hyperparathyroidism in the UK: a chronic kidney disease markov model, Clin Drug Investig, 2010;30:545–57.
| Page 2
| Page 3
| Page 4
| Page 5
| Page 6
| Page 7
| Page 8
| Page 9
| Page 10
| Page 11
| Page 12
| Page 13
| Page 14
| Page 15
| Page 16
| Page 17
| Page 18
| Page 19
| Page 20
| Page 21
| Page 22
| Page 23
| Page 24
| Page 25
| Page 26
| Page 27
| Page 28
| Page 29
| Page 30
| Page 31
| Page 32
| Page 33
| Page 34
| Page 35
| Page 36
| Page 37
| Page 38
| Page 39
| Page 40
| Page 41
| Page 42
| Page 43
| Page 44
| Page 45
| Page 46
| Page 47
| Page 48
| Page 49
| Page 50
| Page 51
| Page 52
| Page 53
| Page 54
| Page 55
| Page 56
| Page 57
| Page 58
| Page 59
| Page 60
| Page 61
| Page 62
| Page 63
| Page 64
| Page 65
| Page 66
| Page 67
| Page 68
| Page 69
| Page 70
| Page 71
| Page 72
| Page 73
| Page 74
| Page 75
| Page 76
| Page 77
| Page 78
| Page 79
| Page 80
| Page 81
| Page 82
| Page 83
| Page 84
| Page 85
| Page 86
| Page 87
| Page 88
| Page 89
| Page 90
| Page 91
| Page 92